Salience Labs Closed Series A Round Led by Applied Ventures and ICM HPQC Fund
7.2.2025 09:14:00 CET | Business Wire | Press release
Appointment of Dr. William Jeffrey to the Board and Bonnie Tomei as CFO
Salience Labs Limited, a leader in photonic solutions targeting connectivity for AI datacenter infrastructure, today announced the successful close of $30 million in Series A financing led by ICM HPQC Fund and Applied Ventures, LLC, the venture capital arm of Applied Materials, Inc., to further the development of its optical switches for large scale AI connectivity. Applied Ventures and ICM HPQC Fund are joined by Strategic Investment Fund, Braavos, and continued participation from existing investors Oxford Sciences Enterprises, Cambridge Innovation Capital, and leaders from the global semiconductor industry including Silicon Catalyst and Jalal Bagherli.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250207290130/en/
Image by Shabbir Bashar
“What our customers want is a photonic switch to connect their AI clusters that is compatible with existing infrastructure while delivering high bandwidth, low latency and significant power savings. The completion of this round will further our development and help us bring our product to customers to enable not just the savings, but large cluster connectivity,” said Vaysh Kewada, Co-founder and CEO of Salience Labs. “We are also excited to be working closely with our strategic investors who are industry leaders to advance our go-to market schedule.”
“Silicon photonics is a promising technology to deliver significant advancements in energy-efficient performance for AI data centers,” said Anand Kamannavar, Vice President and Global Head of Applied Ventures. “Salience's optical switch solution has the potential to enable a new generation of interconnect network architectures for faster and more efficient AI systems.”
“Salience Labs has done a tremendous job in developing a portfolio of innovative silicon photonics products that addresses critical needs in data center and AI infrastructure market,” said Dr. Jalal Bagherli, investor of Salience Labs and former CEO of Dialog Semiconductor that was acquired by Renesas. “Their customer focused approach in addition to the technology that are based on over a decade of research makes Salience Labs a clear leader to win in this enormous market.”
“Salience Lab’s optical switches will enable unprecedented bandwidth and scalability for the next generation of AI and high-performance data centers. By leveraging light, they will unlock the full capability of modern servers while decreasing power consumption and cost. ICM HPQC is excited to work with Vaysh and the Salience team as lead of the Series A raise,” said Dr. William Jeffrey, Chairman of the technical advisory committee on the ICM HPQC Fund and newly appointed Board Member of Salience Labs.
Appointment of Dr. William Jeffrey as new Board Member
In conjunction with the closing of the Series A financing, Salience Labs is appointing Dr. Jeffrey to the Board of Directors, where he joins Jack Edmondson, Chief Investment Officer of Oxford Sciences Enterprises, and Daniel Armbrust, co-founder of Silicon Catalyst, CEO of the SEMATECH semiconductor consortium and appointee to the Industrial Advisory Committee, which advises the Department of Commerce on the R&D strategy for the CHIPS Act.
Dr. Jeffrey is an astronomer with a career spanning the Executive Office of the President of the United States, to leading HRL (known for its groundbreaking innovations such as the invention of the laser, integrated circuits and liquid crystal displays), to being the Director of the National Institute of Standards and Technology, an institution boasting three Nobel prize laureates and ties to a dozen more, and he served as the CEO of SRI International. Dr. Jeffrey earned a Bachelor of Science in physics from the Massachusetts Institute of Technology and a Ph.D. in astronomy from Harvard University.
Appointment of Bonnie Tomei as Chief Financial Officer
Salience Labs is also announcing its appointment of Bonnie Tomei, a certified public accountant and an industry veteran located in Silicon Valley, California, as Chief Financial Officer.
“With over 20 years of experience including initial public offerings, de-SPAC and a strong business operations background, Ms. Tomei will be a key member of the executive team to realize our strategic and operational objectives, including expanding to the U.S. to serve our key customers,” said Ms. Kewada.
About Salience Labs
Salience Labs Limited is a leader in photonic solutions targeting connectivity for AI datacenter infrastructure. Founded in 2021 and backed by over a decade of research from the University of Oxford in the UK and University of Münster in Germany, Salience’s innovative developments in photonic switching technology enable high-speed, ultra-low latency networking fabrics that remove infrastructure bottlenecks for AI workloads. Learn more at http://www.saliencelabs.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20250207290130/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom